Newamsterdam Pharma Co. NV-27NAMSWPreferred / convertible
13F holders, Q1 2024 (March 31)11holders
$11.04avg. 13F price*
At the end of Q1 2024, 11 institutions reported holding Newamsterdam Pharma Co. NV-27 (NAMSW) in their 13F filings. The largest holders were Frazier Life Sciences Management, L.P. ($5.5M), Ra Capital Management, L.P. ($3.7M) and Affinity Asset Advisors, LLC ($2.2M).
- Company
- Newamsterdam Pharma Co. NV-27
- CUSIP
- N62509117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $1.7M |
| Exits | 10 | $1.8M |
Ownership 11 holders
| Frazier Life Sciences Management, L.P. | — | No change | 500,333 | $5.5M |
| Ra Capital Management, L.P. | — | No change | 333,333 | $3.7M |
| Affinity Asset Advisors, LLC | — | Add +47.9% | 202,599 | $2.2M |
| GTS Securities LLC | — | New | 121,150 | $1.3M |
| Bain Capital Life Sciences Investors, LLC | — | No change | 100,000 | $1.1M |
| Deerfield Management Company, L.P. | — | No change | 92,787 | $1.0M |
| Monashee Investment Management LLC | — | New | 31,189 | $344K |
| HRT Financial LP | — | No change | 30,321 | $334K |
| Laurion Capital Management LP | — | No change | 16,666 | $184K |
| Vestcor Inc | — | No change | 9,632 | $106K |
| CIBC Private Wealth Group LLC | — | New | 1,000 | $11K |
"% of holder's portfolio" is NAMSW's weight in each manager's 13F, not the share of Newamsterdam Pharma Co. NV-27 the manager owns.